Zug, Switzerland, May 17 2016 – Renal Dynamics has successfully treated the first patient in its TREAT-HTN prospective, post-marketing multi-center European clinical study to evaluate the safety and efficacy of its third-generation Renal Denervation (ReDy™) System.Read More
Zug, January 15 2016
Shawn Moaddeb, CEO of Renal Dynamics, discusses why you don’t have to create a new product category in order to dominate a market. Shawn explains the key is to uncover what existing products lack, provide an innovative solution, and then communicate the benefits…
Zug, November 4 2015
Renal Dynamics’ (ReDy) third-generation Renal Denervation System received CE clearance and is now commercially available in Europe for treatment of resistant hypertension. The ReDy Renal Denervation System is based on a novel multi-electrode ablation technology that delivers a pre-determined RF ablation set with a single positioning.
Lexington, May 18 2015
Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, will present preclinical data on a third-generation low-profile…
Washington DC, 21 February 2015
Renal Dynamics (ReDy) exhibited pre-clinical results at the Cardiovascular Research Technologies 2015 meeting. Safety and efficacy results on ReDy’s third-generation renal denervation …
Mrs. Sharon Alon
Tel: +1 347-566-6113
Hypertension is a chronic medical condition in which blood pressure in the arteries is elevated. Blood pressure is expressed by two measurements, systolic and diastolic pressures, which are the maximum and minimum pressures, respectively, in the arterial system. Normal blood pressure at rest is within the range of 100-140 mmHg systolic and 60-90 mmHg diastolic. Hypertension is present if the blood pressure is persistently at or above 140/90 mmHg for adults. Sustained hypertension over time is a major risk factor for heart disease, coronary artery disease, stroke, aortic aneurysm, peripheral artery disease and chronic kidney disease. Hypertension affects over 1 billion people worldwide.
About renal denervation
Renal denervation is an interventional approach for the treatment of high blood pressure. A minimally-invasive, endovascular-catheter-based procedure, it uses radiofrequency or ultrasound ablation to treat resistant hypertension. Nerves in the wall of the renal artery are ablated through the application of radiofrequency pulses to the renal arteries. This causes reduction of sympathetic activity in the kidney, resulting in a clinically-relevant decrease in blood pressure.
About Renal Dynamics
Renal Dynamics (ReDy), a member of the Hobart Group of companies, is dedicated to treating hypertension with a single intervention, using its proprietary Renal Denervation System. ReDy is focused on developing a solution that is easy and quick to administer, uses one universal catheter and provides increased patient comfort. For more information, visit Renal-Dynamics.com.
About Hobart Group
The Hobart Group develops and commercializes medical technologies, targeting top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia. For more information, visit www.Hobart-Group.com.